Karin Schölin Bywall
Karin Schölin Bywall
Postdoc researcher
PhD
Karin Schölin Bywall is a postdoc researcher at CRB. She explores patients' preferences and perspectives on individualized treatment using prediction algorithms and digital health applications. The research is part of the NordForsk funded Personalized Medicine in RA by combining genomics, biomarkers, clinical and patient-derived data from the Nordic countries (NORA) project that will develop ways to tailor treatment for individual patients and to integrate patients' own benefit-risk tradeoffs in individualized treatment using digital tools. Karin Schölin Bywall is working with both qualitative exploration and quantitative preference elicitation methods, to explore how people balance their interests and values. She is also part of the IMI-funded PREFER project aiming to investigate methodologies to elicit informed patient preferences regarding the benefits and risks of drugs, from development through the entire cycle, to inform the decision-making process by regulators and HTA bodies.
Email: karin.bywall@crb.uu.se
Phone: +46 18 471 62 49
Recently in the media
- ”Vägen till rätt medicin kan kortas om patienten får vara med i samtalet”
Elsa Science, 2021-06-22 - “A dialogue with the patient can shorten the path to the right medication”
Elsa Science, 2021-06-22 - Patienters syn på att inkluderas i forskning om läkemedel
Reumatikerförbundet, 2018-12-18 - Study explores patient preferences in second-line RA treatment
AJMC, 2021-01-23
Publications
-
Treatment preferences for preventive interventions for rheumatoid arthritis: protocol of a mixed methods case study for the Innovative Medicines Initiative PREFER project
Part of BMJ Open, 2021.
-
Schölin Bywall, Karin
Getting a Say: Bringing patients’ views on benefit-risk into medical approvals
-
An overview of critical decision-points in the medical product lifecycle: Where to include patient preference information in the decision-making process?
Part of Health Policy, p. 1325-1332, 2020.
-
Patient preferences on rheumatoid arthritis second-line treatment: a discrete choice experiment of Swedish patients
Part of Arthritis Research & Therapy, 2020.
-
Patient Perspectives on the Value of Patient Preference Information in Regulatory Decision Making: A Qualitative Study in Swedish Patients with Rheumatoid Arthritis
Part of Patient, p. 297-305, 2019.
-
Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study
Part of Frontiers in Pharmacology, 2019.
-
Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the US
Part of Frontiers in Pharmacology, 2019.
-
Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA
Part of Patient, p. 513-526, 2019.
Risk information
We are investigating risk information from serval perspectives.
Patient preferences
Giving patients a voice in drug development
PREFER is a five year public-private research project where academic researchers and the pharmaceutical industry work together to find out when and where patients want, can and should be involved in drug development
Personalized medicine & preferences
Rheumatoid Arthritis
The NordForsk funded NORA project will develop new ways to tailor treatment for individual patients and to integrate patients' own tradeoffs in individualized treatment using digital tools.
Methodology, rheumatoid arthritis and patient involvement
Drugs should benefit patients. By extension, they should have a say in designing research meant to find out what they think about drugs. Here, Karin Schölin Bywall shares her thoughts about involving patients in research and working together with stakeholders.
